


PHARMACEUTICAL 2019

LANDEC

LANDEC CORP \CA Rank 31 of 371







RealRate

PHARMACEUTICAL 2019

LANDEC CORP \CA Rank 31 of 371



The relative strengths and weaknesses of LANDEC CORP \CA\ are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LANDEC CORP \CA\ compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 727% points. The greatest weakness of LANDEC CORP \CA\ is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 602% points.

The company's Economic Capital Ratio, given in the ranking table, is 137%, being 468% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	97,063
Cost of Goods Sold	445,889
Intangible Assets	54,510
Liabilities, Current	88,375
Liabilities, Non-Current	37,360
Other Assets	93,506
Other Compr. Net Income	622
Other Expenses	-7,413
Other Liabilities	26,406
Other Net Income	3,923
Property and Equipment	159,624
Research and Development	12,800
Revenues	524,227
Selling, General and Administrative Expense	51,951

Output Variable	Value in 1000 USD
Assets	404,703
Liabilities	152,141
Expenses	503,227
Stockholders Equity	252,562
Net Income	24,923
Comprehensive Net Income	25,234
Economic Capital Ratio	137%

